The role of LKB1 in prostate cancer: implications for tumor progression and therapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metabolism

Background:

• Liver kinase B1 (LKB1/STK11) is a critical tumor suppressor in prostate cancer (PCa).
• LKB1 regulates cellular metabolism, epigenetics, and signaling pathways.
• LKB1 loss is linked to metabolic reprogramming, lineage plasticity, and treatment resistance in PCa.

Purpose of the Study:

• To review LKB1-centered networks in prostate cancer.
• To highlight the link between LKB1 inactivation, epigenetic remodeling, and aggressive tumor phenotypes.
• To discuss therapeutic strategies for LKB1-deficient PCa.

Main Methods:

• Literature review of current evidence on LKB1 in PCa.
• Analysis of LKB1's role in metabolic reprogramming and signaling pathways (AMPK/mTOR, STAT3, Hh).
• Examination of LKB1/PTEN co-loss impact on tumor differentiation.

Main Results:

• LKB1 loss dysregulates AMPK/mTOR, STAT3, and Hh pathways, driving PCa progression.
• LKB1 inactivation correlates with epigenetic alterations and aggressive tumor phenotypes.
• Combined LKB1 and PTEN loss significantly impacts tumor differentiation.

Conclusions:

• LKB1-deficient PCa exhibits distinct metabolic and epigenetic vulnerabilities.
• Targeting these vulnerabilities via precision medicine holds promise for improving patient outcomes.
• Biomarker-driven strategies are crucial for addressing treatment resistance in LKB1-deficient PCa.